Lunchtime seminar by Sophia Tickell OHE presentation 6 Oct 2015

1. PharmaDiplomacy Dialogue
Sophia Tickell, Meteos
OHE Seminar
6th October 2015

2. The Origins of PharmaDiplomacy
Unrealised potential for greater alignment:
• Renewed focus on CE and outcomes
• Focus on affordability of interventions as drug
prices rise
• Increasingly vocal debate over what constitutes
‘value’
• Greater patient awareness and empowerment

3. PharmaDiplomacy:
A Dialogue between Health Systems & Pharma
• To identify where and how trust is being eroded
• Use diplomatic skills to improve relations
• Define new agreement mechanisms
• Engage widely with all stakeholders
PharmaDiplomacy aims:

4. PharmaDiplomacy: The Group
• High-level executives from health systems in
the EU and US
–United Health, Geisinger, NICE, MEDEV, RIZIV
• Multi-national pharmaceutical companies
–GSK, J&J, Novo Nordisk
• Patient groups; bioethicists; investors and
health system experts

5. PharmaDiplomacy: The Process
Phase One: Agenda-Setting
Phase Two: Identifying sources of mistrust: pricing
Phase Three: Checklist agreed and written
Phase Four: Consultation
Phase Five: Launch and Outreach

6. The PharmaDiplomacy Checklist
The Checklist is a guidance tool, intended to complement
and enhance other related work.
Designed to:
• Address payer concerns
• Meet needs of patients and
providers
• Support and encourage
pharma innovation
Leading to:
• Mutually acceptable pricing
• Better outcomes
• Increased trust

7. The Checklist
• Identifies issues for discussion at 3 key touch-
points
• Emphasises value of ongoing dialogue
• Ranks issues for discussion by difficulty
• Accommodates difference (systems, payer
priorities and TAs)
Pre/During Phase II Launch/Post-Approval On-Market Review

8. Pre-Phase II Dialogue
• Discussion between
pharma and payers of
meaningful phase III
endpoints and potential
real-world outcomes.

9. Launch/Post-Approval
• Agree which key elements
should influence price
• Engage creatively in risk-
sharing and incentive-based
deals that reward given
outcomes

10. On-Market Price Review
• State commitment to
principle of on-market
price adjustment
• Exploit new technologies to
facilitate outcomes data
capture and track volumes
• Agree practicable review
structures for sharing cost of
data review/collection

11. Enabling Factors
For collaborative approach to gain traction a
number of enabling factors need to be in place:
• Regulatory/Legal Adjustments
• Leadership
• Policy Steers
• Neutral Convener

12. Next Steps
• Undergoing EU/US consultation
• Open invitation to engage:
pharmadiplomacy@meteos.co.uk
• Final conclusions and launch of report in 2016